192 related articles for article (PubMed ID: 26883083)
21. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
22. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients.
Chan KE; Ikizler TA; Gamboa JL; Yu C; Hakim RM; Brown NJ
Kidney Int; 2011 Nov; 80(9):978-985. PubMed ID: 21775975
[TBL] [Abstract][Full Text] [Related]
23. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer.
Yuge K; Miyajima A; Tanaka N; Shirotake S; Kosaka T; Kikuchi E; Oya M
Ann Surg Oncol; 2012 Nov; 19(12):3987-93. PubMed ID: 22872290
[TBL] [Abstract][Full Text] [Related]
25. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model.
Wang L; Cai SR; Zhang CH; He YL; Zhan WH; Wu H; Peng JJ
Chin Med J (Engl); 2008 Nov; 121(21):2167-71. PubMed ID: 19080179
[TBL] [Abstract][Full Text] [Related]
26. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Zhao N; Zhang XC; Yan HH; Yang JJ; Wu YL
Lung Cancer; 2014 Jul; 85(1):66-73. PubMed ID: 24780111
[TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.
Lakhdar R; Al-Mallah MH; Lanfear DE
J Card Fail; 2008 Apr; 14(3):181-8. PubMed ID: 18381180
[TBL] [Abstract][Full Text] [Related]
29. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Hirai T; Yamaga R; Fujita A; Itoh T
J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis.
Jennings DL; Kalus JS; Coleman CI; Manierski C; Yee J
Diabet Med; 2007 May; 24(5):486-93. PubMed ID: 17367311
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Aiko N; Shimokawa T; Miyazaki K; Misumi Y; Agemi Y; Ishii M; Nakamura Y; Yamanaka T; Okamoto H
BMC Cancer; 2018 Oct; 18(1):1012. PubMed ID: 30348116
[TBL] [Abstract][Full Text] [Related]
32. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
33. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
34. The Evaluation of Durative Transfusion of Endostar Combined with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.
Li X; Gu G; Soliman F; Sanders AJ; Wang X; Liu C
Chemotherapy; 2018; 63(4):214-219. PubMed ID: 30347389
[TBL] [Abstract][Full Text] [Related]
35. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
37. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
Steely AM; Callas PW; Bertges DJ;
J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.
Molnar MZ; Kalantar-Zadeh K; Lott EH; Lu JL; Malakauskas SM; Ma JZ; Quarles DL; Kovesdy CP
J Am Coll Cardiol; 2014 Feb; 63(7):650-658. PubMed ID: 24269363
[TBL] [Abstract][Full Text] [Related]
39. Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients.
Yan H; Li Q; Wang W; Zhen H; Cao B
Sci Rep; 2015 Oct; 5():15355. PubMed ID: 26481697
[TBL] [Abstract][Full Text] [Related]
40. Long-term treatment by ACE inhibitors and angiotensin receptor blockers in children with Alport syndrome.
Zhang Y; Wang F; Ding J; Zhang H; Liu X; Wang S; Xiao H; Yao Y; Liu J; Zhong X; Guan N; Su B; Wu G; Yu L
Pediatr Nephrol; 2016 Jan; 31(1):67-72. PubMed ID: 26248473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
